Predicting surgery success after chemotherapy for pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate new diagnostic tools to predict surgical resectability in patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma who receive neoadjuvant chemotherapy with FOLFIRINOX. It will utilize diffusion-weighted magnetic resonance imaging, radiomics, and liquid biopsy analyses to improve the accuracy of surgical predictions. The study will compare these innovative diagnostic methods against standard imaging techniques to identify patients who may benefit from surgery and avoid unnecessary procedures. Additionally, it will assess postoperative outcomes and survival rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female patients, aged 18 years and above
* Diagnosis of BR or LA PDAC according to NCCN guidelines (version 1.2020)
* Histologic diagnosis of PDAC
* No medical or anesthetic contra-indication for surgery
* Able to understand nature of the study procedures
* Willing to participate and give written informed consent

Exclusion Criteria:

* Age \< 18 years
* Distant metastases
* Histologic diagnosis of cholangiocarcinoma, duodenal carcinoma or neuroendocrine tumor
* Known hypersensitivity for MRI contrast
* Pacemaker or prosthesis with incompatibility for MRI
* Claustrophobia
* Pregnancy or breastfeeding
* Not able to understand nature of the study procedure
* Performance status ECOG score: \>2

Where it's running

• Ghent University Hospital
  Ghent, East Flanders, Belgium Recruiting
• AZ Sint Blasius Dendermonde
  Dendermonde, Belgium Recruiting
• AZ Alma Eeklo
  Eeklo, Belgium Recruiting
• AZ Jan Palfijn Ghent
  Ghent, Belgium Recruiting
• AZ Sint Lucs Ghent
  Ghent, Belgium Recruiting
• AZ Oudenaarde
  Oudenaarde, Belgium Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer

  This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07895498

• Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer

  This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.

  Recruiting Ningbo Medical Center Lihuili Hospital · Ningbo, Zhejiang · NCT07892573

• Blood protein biomarkers to help diagnose pancreatic cancer in adults

  This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.

  Recruiting Grigore T. Popa University of Medicine and Pharmacy · Iași · NCT07875582

• Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Cancer (Phase 1)

  This early-stage study tests whether giving Lm-LLO-TT directly into the belly with low-dose gemcitabine is safe and tolerable for adults with previously treated, unresectable or metastatic pancreatic cancer.

  Recruiting Phase 1 Matter Bio, Inc. · The Bronx, New York · NCT07828236

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.